Table 3 Linear regression results for anti-S antibody AUC at visit 3 and visit 4 for both PFOA (top) and PFOS (bottom).
Anti-S antibody AUC at visit 3 | Anti-S antibody AUC at visit 4 | |||
|---|---|---|---|---|
Percent change (95% CI) | P value | Percent change (95% CI) | P value | |
PFOA concentration | 14.9 (−8.9, 38.7) | 0.22 | 4.6 (−13, 22.1) | 0.61 |
Age | −2.7 (−4.5, −0.9) | <0.01 | −3.1 (−4.4, −1.8) | <0.01 |
Female vs. male | −20.3 (−56.6, 46.2) | 0.46 | 13.7 (−27.9, 79.2) | 0.58 |
Geographical site: 2 vs. 1 | −21.1 (−63.2, 69.2) | 0.54 | −4.4 (−44.9, 65.7) | 0.87 |
History of COVID-19 (naive vs. recovered) | 92.9 (3.5, 259.6) | 0.04 | 21.8 (−22.8, 92.1) | 0.4 |
Vaccine Brand (Moderna vs. Pfizer-BioNTech) | −22.5 (−67.3, 83.4) | 0.56 | −26.3 (−58.1, 29.5) | 0.29 |
PFOS concentration | 5.8 (−21.6, 33.3) | 0.68 | 8.5 (−12.4, 29.4) | 0.43 |
Age | −2.7 (−4.5, −0.9) | <0.01 | −3.2 (−4.4, −1.9) | <0.01 |
Female vs. Male | −22.4 (−57. 9, 43.3) | 0.42 | 15 (−27.1, 81.3) | 0.55 |
Geographical site: 2 vs. 1 | −37.1 (−67.9, 23.1) | 0.18 | −5.4 (−41.5, 52.9) | 0.82 |
History of COVID-19 (naive vs. recovered) | 94.1 (3.7, 263.3) | 0.04 | 22.1 (−22.6, 92.6) | 0.39 |
Vaccine Brand (Moderna vs. Pfizer-BioNTech) | −16.5 (−64.8, 98) | 0.68 | −27 (−58.4, 28.3) | 0.28 |
